fashion -WSS

fashion

author：explore 2025-09-28 01:40:06 - browse：75

Julia Rendleman/Getty Images for Eventive Marketing

Health insurer Cigna is paying more than $172 million to settle allegations that it committed fraud by knowingly submitting inaccurate diagnoses of its Medicare Advantage members, the company and Department of Justice announced Saturday.

The settlement stems from a wide-ranging government investigation into the coding practices of Medicare Advantage insurers, as well as a specific whistleblower lawsuit against Cigna that the DOJ joined last year.

That lawsuit alleged Cigna’s home visit program “regularly generated false and invalid diagnosis codes for certain serious, complex conditions that cannot be reliably diagnosed in a home setting and without extensive diagnostic testing or imaging,” the DOJ said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： How to save health care price transparency rules

explore

WSS

J&J lung cancer data amount to new salvo against AstraZeneca

Why scientists need input from humanists on sensitive research

Study on Amgen’s bispecific immunotherapy produces positive data

Change Healthcare outage fallout shows need for new oversight

Questions loom on AstraZeneca cancer drug as safety concerns ebb

First U.S. drug developed to treat liver disease MASH is approved

hotspot

fashion

explore

Alkermes shareholders re

President Biden's budget: Here's what you might have missed

Moonlake's readout produced a cash windfall. Risks remain

UCLA team creates talking throat patch for voice disorders

Heart attack and stroke risk calculators need revising

Questions loom on AstraZeneca cancer drug as safety concerns ebb

In Memoriam: Notable people who died in 2023

WuXi out of biotech trade group, U.S. and China relations to blame

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

hotspot

Results on Novartis prostate cancer therapy could expand its use

UCLA team creates talking throat patch for voice disorders

Why depression after traumatic brain injury is distinct

Roivant's CEO is a star, but biotech's black hole persists

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Male and female sex labels in research insufficient, scientists say

hotspot

knowledge

explore

Wikipedia